Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra

Shashidhar S. Jatiani; Adolfo Aleman; Deepu Madduri; Ajai Chari; Hearn Jay Cho; Shambavi Richard; Joshua Richter; Joshua Brody; Sundar Jagannath; Samir Parekh

doi:10.1016/j.clml.2020.04.020

Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra

Shashidhar S. Jatiani, Adolfo Aleman, Deepu Madduri, Ajai Chari, Hearn Jay Cho, Shambavi Richard, Joshua Richter, Joshua Brody, Sundar Jagannath, Samir Parekh

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Original language	English
Pages (from-to)	632-636.e1
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	20
Issue number	9
DOIs	https://doi.org/10.1016/j.clml.2020.04.020
State	Published - Sep 2020

Keywords

Anakinra
CAR-T cell therapy
Cytokine release syndrome
Multiple myeloma
Tocilizumab

Access to Document

10.1016/j.clml.2020.04.020

Cite this

@article{9b0066f2f4284fb99d65caf69895ff13,

title = "Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra",

keywords = "Anakinra, CAR-T cell therapy, Cytokine release syndrome, Multiple myeloma, Tocilizumab",

author = "Jatiani, {Shashidhar S.} and Adolfo Aleman and Deepu Madduri and Ajai Chari and Cho, {Hearn Jay} and Shambavi Richard and Joshua Richter and Joshua Brody and Sundar Jagannath and Samir Parekh",

note = "Funding Information: S. Parekh is funded by 1R01CA244899-01A1. This project is supported by the Tisch Cancer Institute at Mount Sinai ( P30 CA196521 – Cancer Center Support Grant). Assistance of the shared resources from Mount Sinai Human Immune Monitoring core is gratefully acknowledged. Funding Information: A. Chari is a paid consultant for Amgen, Bristol Myers Squibb, Celgene, Antegene, Takeda, Janssen, and Karyopharm; has received research funding from Amgen, Array BioPharma, Celgene, Glaxo Smith Klein, Janssen, Takeda, Novartis, Oncoceutics, Pharmacyclics, and Seattle Genetics; is an advisory board member for Amgen, Celgene, Millennium/Takeda, Janssen, Karyopharm, Sanofi, and Seattle Genetics. H. J. Cho is a paid consultant for the MMRF; has received research funding from Takeda, Celgene, and Genentech. D. Madduri is a consultant for Janssen, Celgene, AbbVie, Takeda, and Foundation of Medicine. J. Richter is part of the speaker's bureau at Celgene and Janssen; part of the Advisory Board for Celgene, Janssen, Bristol Myers Squibb, Oncopeptides, Adaptive Biotechnologies, X4 Pharmaceuticals, Karyopharm, and Antegene. S. Jagannath is a paid consultant for AbbVie, Celgene, Bristol Myers Squibb, Karyopharm, Janssen, and Merck. S. Parekh is a paid consultant for Foundation Medicine; and has received research funding from Celgene and Karyopharm. All other authors state that they have no conflicts of interest.S. Parekh is funded by 1R01CA244899-01A1. This project is supported by the Tisch Cancer Institute at Mount Sinai (P30 CA196521 ? Cancer Center Support Grant). Assistance of the shared resources from Mount Sinai Human Immune Monitoring core is gratefully acknowledged.",

year = "2020",

month = sep,

doi = "10.1016/j.clml.2020.04.020",

language = "English",

volume = "20",

pages = "632--636.e1",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "9",

}

TY - JOUR

T1 - Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra

AU - Jatiani, Shashidhar S.

AU - Aleman, Adolfo

AU - Madduri, Deepu

AU - Chari, Ajai

AU - Cho, Hearn Jay

AU - Richard, Shambavi

AU - Richter, Joshua

AU - Brody, Joshua

AU - Jagannath, Sundar

AU - Parekh, Samir

N1 - Funding Information: S. Parekh is funded by 1R01CA244899-01A1. This project is supported by the Tisch Cancer Institute at Mount Sinai ( P30 CA196521 – Cancer Center Support Grant). Assistance of the shared resources from Mount Sinai Human Immune Monitoring core is gratefully acknowledged. Funding Information: A. Chari is a paid consultant for Amgen, Bristol Myers Squibb, Celgene, Antegene, Takeda, Janssen, and Karyopharm; has received research funding from Amgen, Array BioPharma, Celgene, Glaxo Smith Klein, Janssen, Takeda, Novartis, Oncoceutics, Pharmacyclics, and Seattle Genetics; is an advisory board member for Amgen, Celgene, Millennium/Takeda, Janssen, Karyopharm, Sanofi, and Seattle Genetics. H. J. Cho is a paid consultant for the MMRF; has received research funding from Takeda, Celgene, and Genentech. D. Madduri is a consultant for Janssen, Celgene, AbbVie, Takeda, and Foundation of Medicine. J. Richter is part of the speaker's bureau at Celgene and Janssen; part of the Advisory Board for Celgene, Janssen, Bristol Myers Squibb, Oncopeptides, Adaptive Biotechnologies, X4 Pharmaceuticals, Karyopharm, and Antegene. S. Jagannath is a paid consultant for AbbVie, Celgene, Bristol Myers Squibb, Karyopharm, Janssen, and Merck. S. Parekh is a paid consultant for Foundation Medicine; and has received research funding from Celgene and Karyopharm. All other authors state that they have no conflicts of interest.S. Parekh is funded by 1R01CA244899-01A1. This project is supported by the Tisch Cancer Institute at Mount Sinai (P30 CA196521 ? Cancer Center Support Grant). Assistance of the shared resources from Mount Sinai Human Immune Monitoring core is gratefully acknowledged.

PY - 2020/9

Y1 - 2020/9

KW - Anakinra

KW - CAR-T cell therapy

KW - Cytokine release syndrome

KW - Multiple myeloma

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=85086449161&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2020.04.020

DO - 10.1016/j.clml.2020.04.020

M3 - Article

C2 - 32553791

AN - SCOPUS:85086449161

SN - 2152-2650

VL - 20

SP - 632-636.e1

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 9

ER -